Biological bank for patients with autoimmune cytopenia
Official title: Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
Run by University Hospital, Bordeaux · NCT04005638 · Data updated 2026-11-12
This study is setting up a collection of biological samples from patients with autoimmune cytopenia to help researchers learn more about these conditions and find better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Pessac) |
| Status | Recruiting |
| Started | February 2, 2019 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | March 26, 2025 |
| Trial ID | NCT04005638 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients over 16 years old diagnosed with autoimmune cytopenia who can provide informed consent.
✕Probably not a fit
Patients who are currently undergoing treatment for autoimmune cytopenia or those with viral infections such as HIV or Hepatitis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a biological bank for patients diagnosed with autoimmune cytopenia, including immune thrombocytopenia, autoimmune hemolytic anemia, and autoimmune neutropenia. The research is conducted by the Internal Medicine Department of Haut-Lévêque Hospital, which has been recognized as a reference center for these conditions. The biological samples collected will support translational and fundamental research, facilitating collaboration between clinical departments and research units to explore the underlying mechanisms of these disorders and develop new treatment options.
Why it matters
Potential benefit: If successful, this initiative could lead to advancements in understanding and treating autoimmune cytopenias, ultimately improving patient outcomes.
How similar studies have gone: While this approach is not entirely novel, similar studies have shown promise in utilizing biological banks for advancing research in autoimmune diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 16 years old. * Patients with autoimmune cytopenia according to the definitions reported in the latest update of the French National Care Protocol (PNDS 2017). * Affiliated person or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Positivity for HIV, Hepatitis C or B virus. * Pregnant or lactating woman. * Patient undergoing treatment for autoimmune cytopenia
Where it's running
-
CHU de Bordeaux - service de médecine interne
Pessac, France Recruiting
Study contacts
- Principal investigator: Jean-François VIALLARD, Prof — University Hospital, Bordeaux
- Study coordinator: Jean-François VIALLARD, Prof
- Email: jean-françois.viallard@chu-bordeaux.fr
- Phone: 05.57.65.64.83
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluation of diagnosis and treatment for autoimmune cytopenias
This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.
-
National cohort for pediatric autoimmune cytopenia
This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.
-
Registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
This study is collecting information from adults in France who have recently been diagnosed with immune thrombocytopenia or autoimmune hemolytic anemia to better understand these conditions and how well different treatments work in real life.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
-
GL-2045 safety and blood-count help for adults with ITP
GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.